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doi:10.1016/j.ejvs.2008.12.004Abstract Aortic dissection is an uncommon but a highly lethal condition. Dissection of the
ascending aorta is associated with a mortality rate of 1e2% per hour within the first 24 h
and should be managed by an open surgery. An uncomplicated, acute, type B dissection, which
should be treated medically, is less frequently lethal, with survival rates of 84% within 1 year.
Unfortunately, long-term outcome of medical therapy alone is suboptimal, with a reported
30e50% mortality rate at 5 years and a delayed expansion of the false lumen in 20e50% of
patients at 4 years. In this setting, endovascular treatment should be considered when the
aortic diameter exceeds 55e60 mm, in case of uncontrolled pain, blood pressure and rapid
growth of the dissecting aneurysm (>1 cm per year). About 30e42% of acute, type B aortic
dissections are complicated, as evidenced by haemodynamic instability or peripheral vascular
ischaemia with a mortality rate of 50e85% if not treated properly. In this scenario, stent-graft
repair is an attractive alternative to surgical repair for correcting ischaemic complications.
The long-term therapy of patients with aortic dissection includes aggressive medical therapy,
follow-up visits and serial imaging.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Aortic dissection is an uncommon but a highly lethal
condition, with an estimated incidence ranging from 3 to 8
cases per 100, 000 persons.1e3 Approximately, 0.5% of
patients presenting to an emergency department with
chest or back pain suffer from aortic dissection or itser, Tel.: þ49 (0)381 494 77
aber@med.uni-rostock.de
o this manuscript.
ty for Vascular Surgery. Publisheprecursors.4 Men are twice as often found to suffer from
acute aortic dissection than women, with 60% of dissection
cases classified as proximal or type A and 40% as distal or
type B according to the Stanford classification.1 The
historical data of untreated aortic dissection of the
ascending aorta show a mortality rate of 1e2% per hour
within the first 24 h, resulting in a mortality rate of up to
50e74% within the first 2 weeks.1,2 An uncomplicated,
acute, type B dissection is less frequently lethal, with
survival rates of 89% in medically treated patients at 1
month, 84% within 1 year and up to 80% within 5 years.1,5d by Elsevier Ltd. All rights reserved.
Table 1 Distribution of differential therapeutic strategies
in aortic dissection
Surgery
Type A aortic dissection
Acute type B dissection complicated by
Retrograde extension into the ascending aorta
Dissection in fibrillinopathies (e.g., Marfan’s syndrome,
EhlerseDanlos syndrome)
Medical
Uncomplicated, acute type B dissection
Stable, isolated aortic arch dissection
Chronic type B dissection
Interventional
Unstable, acute type B dissection
Malperfusion
Rapid expansion (>1 cm per year)
Critical diameter (5.5 cm)
Refractory pain
Stable type B dissection (under evaluation)
290 I. Akin et al.However, patients with acute or late complications,
including renal failure, visceral ischaemia or contained
rupture, often require urgent repair, with a mortality rate
mounting to 20% at day 2, and 25e50% within 1 month.1
Similar to type A dissection, advanced age, rupture, shock
and malperfusion are important independent predictors of
early mortality in type B dissection.6,7 While almost every
patient with a type A dissection should be managed by open
surgery, endovascular concepts have emerged as an alter-
native therapeutic option to manage acute and chronic
aortic dissections, mainly distal thoracic aortic dissection.
For proximal or type A dissection, any endovascular
approach remains experimental and anecdotal for localised
pathologies in patients unfit for surgical therapy. Although
dissection of the aorta is an acute event, in most cases, an
underlying chronic and generalised disease of the media
vessel wall predisposes the aorta to chronic alterations,
eventually leading to dissection.
In this article, we review current indication, timing and
results of endovascular management of patients with type B
aortic dissection in the context of the recent literature.Type B dissection with retrograde extension into the
ascending aorta
Hybrid procedure for extended type A aortic dissectionIndication for Stent-graft Repair in
Type B Aortic Dissection
The natural course of aortic dissection is determined by two
elements: early complications and chronic events. Early
complications comprise any kind of malperfusion syndrome
or rupture, while late events are usually a continued false
lumen expansion with the risk for late rupture. Once
a patient survives the first 2 weeks after the impact of
dissection, the process is defined as chronic. Acute and
chronic dissections differ considerably with respect to
medical treatment, taking into consideration that even
acute dissections can be complicated or uncomplicated.
The feasibility of stent grafting of the descending
thoracic aorta has already been established as an alterna-
tive to surgical treatment of type B aortic dissection.
However, due to the lack of both randomised controlled
trials with long-term follow-up data and randomised
comparisons with medical and surgical techniques, the
indications for endovascular strategies remain to be fully
defined for dissection (Table 1). There is clear observa-
tional evidence that depressurisation and shrinkage of the
false lumen are beneficial in acute dissection, ideally fol-
lowed by complete thrombosis of the false lumen and
remodelling of the entire dissected aorta. Similar to
previously accepted indications for surgical intervention,
scenarios such as intractable pain, rapidly expanding false
lumen, diameter >55 mm and signs of imminent rupture or
distal malperfusion are increasingly being accepted as
indications for stent-graft placement in type B dissec-
tion.8,9 Even in some cases of retrogradely extended type A
dissections, stent-graft treatment of the descending
thoracic aorta can also be performed as a single step or as
two steps after initial surgical repair of the proximal part of
the aorta or the arch. Open surgery may include an
elephant trunk or transposition of arch vessels to allow
optimal landing zones for endovascular completion in
a hybrid approach. In case of retrograde type A dissection,
an isolated distal-entry tear can sometimes be sealed bya stent graft, hence enabling thrombosis and remodelling
even of the proximal false lumen in type A dissection. With
endografting, paraplegia generally appears to be a rare
phenomenon (0.8%), but is known to be associated with
extensive coverage of the aorta exceeding 20 cm and with
the use of multiple stent grafts, or in case of previously
operated aortas.10
Stable, Acute, Type B Aortic Dissection
Patients with suspected acute aortic dissection should be
admitted to the intensive care unit for prompt diagnostical
evaluation under clinical and haemodynamic monitoring.
Reduction of systolic blood pressure to 100e120 mmHg,
with an eye on the renal function and pain relief, is the
initial priority and is achieved by morphine sulphate and
intravenous beta-blocking agents (e.g., metoprolol, esmo-
lol or labetolol) or by a combination with vasodilating drugs
such as sodium nitropusside, at a dose of 0.3 mg kg1 min1,
or angiotensin-converting enzyme inhibitors. Intravenous
verapamil or diltiazem may also be used, if beta-blocking
agents are contraindicated. A monotherapy with beta-
blocking agents may be adequate to control mild hyper-
tension (Table 2). In addition, heart rate should be kept low
e a heart rate below 60 bpm significantly decreases
secondary adverse events (aortic expansion, recurrent
aortic dissection, aortic rupture and/or need for aortic
surgery) in type B aortic dissection compared to a conven-
tional rate of more than 60 bpm.11 Once both stable blood
pressure and symptom relief are achieved, the patient with
an acute, uncomplicated, type B aortic dissection can be
discharged (usually within 14 days), and clinical and
imaging follow-up should be offered and advised at 3 and 6
months and annually thereafter. In a series of 384 patients
with type B dissections from the International Registry of
Figure 1 Comparison of medical, surgical and endovascular
treatment in patients with acute type B aortic dissection.21
Table 2 Initial medical treatment in aortic dissection
Name Mechanism Dose Cautions/contraindications
Esmolol Cardioselective
beta-1 blocker
Load: 500 mg kg1 IV Asthma or bronchospasm
Drip: 50 mg kg1 min1 IV Bradycardia
Increase by increments of
50 mg min1
2nd- or 3rd-degree AV block
Cocaine or methamphetamine abuse
Labetalol Non-selective
beta-1,2 blocker
Load: 20 mg IV Asthma or bronchospasm
Selective alpha-1
blocker
Drip: 2 mgmin1 IV Bradycardia
2nd- or 3rd-degree AV block
Cocaine or methamphetamine abuse
Enalaprilat ACE inhibitor 0.625e1.25 mg IV q 6 h Angio-oedema
Max dose: 5 mg q 6 h Pregnancy
Renal artery stenosis
Severe renal insufficiency
Nitroprusside Direct arterial
vasodilator
Begin at 0.3 mg kg1 min1 IV. May cause reflex tachycardia
Max dose 10 mg kg1 min1
Cyanide/thiocyanate toxicity e especially
in renal or hepatic insufficiency
Nitroglycerin Vascular smooth
muscle relaxation
5e200 mg min1 IV Decreases preload e contraindicated in
tamponade or other preload-dependent states
Concomitant use of sildenafil or similar agents
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cally with an in-hospital mortality of 10%.1,7,12 The short-
term survival rates were 91% at 1 month and 89% at 1 year.
The reported long-term survival rate with medical therapy
varies between 60% and 80% at 4e5 years and is around
40e45% at 10 years.1,2,7,12 Yet again, the predictors of early
mortality were malperfusion, hypotension, lack of chest or
abdominal pain and partial thrombosis of the false
lumen.7,13
Unstable, Acute, Type B Aortic Dissection
About 30e42% of the acute type B aortic dissections are
complicated, as evidenced by haemodynamic instability or
peripheral vascular ischaemia.12 In contrast to the previ-
ously described stable, acute dissection, unstable patients
have a highly unpredictable outcome. Among other
complications, acute lower limb and visceral ischaemia
have been reported in 30e50% of patients; malperfusion
syndrome occurs frequently in cases of distally extended
dissections and may lead to death in 50e85% of patients if
not treated properly.5,14,15 In a necropsy study of 18
patients with type B dissection, a compression of the true
aortic lumen with aortic obstruction was evident in 56% of
patients.16 One mechanism of malperfusion may be the
result of either static extension of the dissection flap
directly into the orifice of a visceral or lower-limb artery,
thereby narrowing its lumen, or of a dynamic obstruction of
the vessel by means of the flap prolapsing into the vesselorigin. Once diagnosed, these complications require
emergent therapeutic action. However, despite a wide
array of open surgical strategies, operative mortality rate
for patients with acute aortic dissection, complicated by
Figure 2 Comparison of elective- and emergency-treated
patients with type B aortic dissection. Data from the TTR
registry.48
292 I. Akin et al.renal ischaemia, has been reported as high as 50%, and
even 88% when mesenteric perfusion is impaired.17e20
Fattori et al. compared the impact on survival of different
treatment strategies in 571 patients with acute type B
aortic dissection.21 Of the 571 patients with acute type B
aortic dissection, 390 (68.3%) were treated medically;
among the complicated cases, 59 (10.3%) underwent stan-
dard open surgery and 66 (11.6%) were subjected to an
endovascular approach. The in-hospital mortality was
significantly higher after open surgery (33.9%) than after
endovascular treatment (10.6%; pZ 0.002) for those
patients with complicated type B aortic dissection (Fig. 1).
Thus, stent-graft repair is an attractive alternative to
surgical repair for correcting ischaemic complications
(Fig. 2)48. Usually, stent-graft occlusion of the entry site inFigure 3 Malperfusion of distal aorta by occlusive type B dissec
descending aorta re-established flow to the abdomen and legs.the descending thoracic aorta results in thrombosis of the
false lumen and predominant flow in the true lumen, thus
normalising distal-vessel perfusion and restoring branch-
vessel patency22 (Fig. 3). The PETTICOAT (provisional
extension to induce complete attachment) concept takes
the idea even further by extending the stent-graft scaffold
distally with open-cell bare-metal stents. For instance, if
malperfusion persists after coverage of the primary entry
tear, additional distal open stents are the devices deployed
until distal malperfusion is corrected.23 With this concept,
aortic fenestration manoeuvres or branch-vessel re-vascu-
larisation with uncovered stent are usually not needed and
almost obsolete.
The EUROSTAR/United Kingdom registry report repre-
sents a first large series of patients treated with thoracic
aortic stent grafts; in this combined registry, 131 patients
with aortic dissection (5% proximal, 81% distal and 14% not
classified) were treated with stent grafts, with 57% of
patients presenting with symptoms of rupture, aortic
expansion or side-branch occlusion. Although meaningful
long-term data are still lacking, primary technical success
was achieved in 89% of patients, at the expense of a 30-day
mortality rate of only 8.4%.24 A series of patients at the
Arizona Heart Institute, comprising 40 patients (23 acute
and 17 chronic) treated with a thoracic endograft for
complicated, distal, aortic dissection, enjoyed a technical
success rate of 95%. There was one peri-operative death
due to iliac rupture and one case of paraplegia, while 15
patients (38%) experienced transient postoperative
complications, mostly renal and pulmonary, the 1-year
survival rate was 85%. Of the patients available for follow-
up computed tomography (CT), 97% (30 of 31 patients)
exhibited a stable or decreasing aortic diameter and no
rupture occurred during the observational period, there-
fore justifying the conclusion that thoracic aortic stent
grafting obviously stabilised the aorta and decreased thetion. Stent-graft placement in the true lumen of the proximal
Table 3 Results of endovascular stent-graft implantation in different clinical conditions
Author Year n Technical success (%) Paraplegia (%) Mortality (%) Follow-up (month)
Acute complicated type B dissection
Beregi8 2003 46 96 n.a. 17 8
Bortone45 2004 43 100 0 7 21
Leurs24 2004 131 89 0.8 8.4 12
Eggebrecht10 2006 609 98 0.8 11.2 24
Chen27 2006 62 100 0 4.8 1
Xu46 2006 63 95 0 10.6 48
Schoder26 2007 28 86 3.6 10.7 36
Verhoye28 2008 16 100 0 27 36
Fattori21 2008 66 100 3.4 10.6 1
Szeto47 2008 35 97.1 2.8 2.8 18
Chronic type B dissection
Nienaber37 1999 12 100 0 0 12
Kato38 2001 15 100 0 0 24
Eggebrecht35 2005 28 100 0 13.6 12
Chen27 2006 19 100 0 11 27
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analysis of the literature from 2000 to 2004 replicated those
results on patients subjected to endovascular stent-graft
repair of aortic dissection in 609 patients.10 Procedural
success was obtained in 98.2% of patients, with an in-
hospital surgical conversion rate of 2.3% and an in-hospital
mortality rate of 5.2%. Complications such as retrograde
extension of the dissection into the ascending aorta were
reported in 1.9% and neurological complications in 2.9% of
patients. The 30-day mortality rate and in-hospital
complications were documented more often in patients
undergoing stent-graft treatment for acute aortic dissec-
tion as compared to patients undergoing treatment for
chronic aortic dissections (9.8% vs. 3.2% and 21.7% vs. 9.1%,Figure 4 Type B aortic dissection in a 48-year-old man; note tha
acute phase. In the chronic phase, there is still a partial perfusio
stent-graft placement across the proximal thoracic entry, the entir
with complete ‘healing’ of the dissected aortic wall and shrinkingrespectively; p< 0.05). Schoder et al. reported a 30-day
mortality of 10.7% in a series of 28 patients with compli-
cated type B aortic dissection; at 1-year follow-up, the
false lumen was thrombosed in 90% of the patients, and the
mean difference of diameter reduction was highly signifi-
cant.26 Similar results were reported by Chen et al. in their
series of 62 patients.27 In a series of 16 patients with
complicated, acute, type B aortic dissection treated with
stent grafts within 48 h after presentation, Verhoye et al.
reported an early mortality rate of 25%, with no late death
and a 5-year survival rate of 73%.28 In a single series in
which the indication for stent grafting was strictly applied
to those deemed unsuitable candidates for conventional
open surgical repair, the 1- and 5-year survivals were 74%t there is a dynamic obstruction of the true lumen (TL) in the
n of the false lumen with additional partial thrombosis. After
e true lumen of the thoracic aorta is reconstructed with time,
of the completely thrombosed false lumen (FL). TH: thrombus.
294 I. Akin et al.and 31%, respectively, after stent grafting compared to 93%
and 78% (p< 0.001) survival rates, respectively, after stent
grafting in patients who were reasonable candidates for
conventional open repair.29 Interestingly, a comparison
between endovascular treatment of complicated type B
aortic dissection with medical therapy of uncomplicated
type B dissections in 56 patients and a follow-up of
18.1 16.9 months reported similar outcomes in both
groups with better mid-term fate of the descending
thoracic aorta in the stent-graft group, no paraplegia and
no differences in the 5-year survival rate (86.3% in both
groups)30 (Table 3).
Chronic Type B Aortic Dissection
The evolution of an acute dissection to a chronic dissection
involves progressive thickening of the intimal flap due to
fibrosis. In addition, more intimal tears are reported in
chronic type B aortic dissection compared to acute
dissection. The growth rate of the chronically dissected
distal aorta is estimated to range from 0.1 to 0.74 cm per
year depending on both the initial aortic diameter and the
state of hypertension.31,32 Unfortunately, the long-term
outcome of medical therapy alone is suboptimal, with
a reported mortality rate of 50% at 5 years and delayed
expansion of the false lumen in 20e50% patients at 4
years.1,33 This expansion of the false lumen, for which an
initial diameter of more than 4 cm and a persistent perfu-
sion of the false lumen were determined as predictors,
predisposes patients to aortic rupture or retrograde
migration of the dissection towards the ascending aorta
with an increased mortality rate.34,35 Spontaneous throm-
bosis of the false lumen has been identified in <4% of
patients.36 Endovascular treatment should be considered
when the aortic diameter exceeds 55e60 mm, when
permanent thoracic pain occurs or in case of uncontrolled
blood pressure and rapid growth of the dissecting aneurysm
(>1 cm per year) (Fig. 4). Nienaber et al. prospectively
evaluated stent-graft management in 12 patients with
chronic type B dissection and compared the results with 12
matched surgical controls. Proximal entry closure and
complete thrombosis of the false lumen at 3 months were
achieved in all the patients. Stent-graft treatment resulted
in no morbidity or mortality, whereas surgical treatment
resulted in four deaths (33%; pZ 0.04) and five adverse
events (42%; pZ 0.04).37 Similar results were obtained by0 12 months 36
RRR
7,6% 
Acute/subacute
[SG ≤ 3 month]
Chronic
[SG > 3 month] 0,71
0,92
p = 0,023
RRR
12,0%
1.0
0.6
0.7
0.8
0.9
0.5
n = 84
Figure 5 Impact of treatment timing on event (MAVE) free
survival in patients with acute aortic dissection (own results).Kato in a series of 15 patients with no mortality during
a follow-up of 2 years.38 Eggebrecht et al. compared the
clinical outcome of 38 patients with type B aortic dissection
(10 acute and 28 chronic) after endovascular stent-graft
treatment. They observed significantly lower in-hospital
mortality and a trend towards better 4-year survival rate in
patients with underlying chronic aortic dissection39 (Table 3).
Whether a prophylactic implantation of stent graft in
patients with chronic type B aortic dissections is superior to
medical treatment alone is actually under long-term follow-
up evaluation in the prospective, randomised, controlled
INSTEAD trial.34 At 12 months, KaplaneMeier life-table
analysis showed no mortality advantage of prophylactic
stent-graft placement. The 2-year results are expected to be
published.3,4
Timing of Endovascular Repair
The optimal timing for endovascular intervention in type B
dissections remains controversial. In 2002, Bortone et al.
defended an immediate intervention within 2 weeks of the
initial diagnosis; a stent-graft placement was successful in
all the patients referred for intervention within the first 2
weeks.40 Conversely, others have obtained higher mortality
rates in patients with acute type B aortic dissection
compared to patients with chronic aortic dissections.39
Kato et al. speculated that morphological changes of the
initially fragile dissecting membrane to a more fibrotic and
seemingly stable membrane in the chronic phase are crit-
ical for endovascular repair and recommend a treatment
after a minimum period of 4 weeks after the onset of aortic
dissection.41 In addition, the more stable clinical status of
the patients in the chronic phase of aortic dissection may
be an important determinant of better survival following
endovascular repair. On the other hand, patients with acute
aortic dissection have the greater potential for stent-graft-
induced complete remodelling of the entire aorta (Fig. 5).
Shimono et al. reported that complete obliteration and
resolution of the false lumen following endovascular stent-
graft treatment were more frequently achieved in patients
with acute aortic dissection compared to patients with
chronic aortic dissection (70% vs. 38.5%).42 In fact, due to
lack of prospective randomised data comparing immediate
and delayed intervention in various clinical and anatomical
constellations, no general recommendation has been issued
with respect to timing of endovascular treatment so far;
observational evidence, however, may favour an early
intervention, when justified by complications.
Long-Term Follow-Up and Adjunctive
Treatment
The long-term approach to patients with successful initial
treatment of aortic dissection begins with an appreciation
that such patients have a systemic illness that invariably
involves the entire aorta and branches as targets for future
complications. Systemic hypertension, advanced age,
aortic size and presence of patent false lumen are all
factors that identify higher risk.33,43 Therefore, all patients
deserve aggressive medical therapy, follow-up visits and
surveillance, including serial imaging. Treatment with
Indication, Timing and Results of Endovascular Treatment of Type B Dissection 295effective beta-blocking agents, and potentially sartans, is
the cornerstone of medical therapy regardless of whether
their in-hospital definitive treatment was surgical, medical
or interventional. Pure vasodilators, such as dihydropyr-
idine calcium-channel antagonists or hydralazin, may cause
an increase in dP/dt and should therefore be used only in
conjunction with adequate beta-blockade. ACE inhibitors
are attractive antihypertensive agents for treating aortic
dissection and may be of particular benefit in patients with
some degree of renal ischaemia as a consequence of the
dissection. Late aneurysm rupture after aortic dissection is
10 times more common in patients with poorly controlled
hypertension than in those with controlled blood pres-
sure.33 The guidelines recommend progressive up-titration
of dosage to achieve a blood pressure <135/80 mmHg.1,2,44
Serial imaging for the aorta is an essential component of
long-term treatment and follow-up of patients with aortic
aneurysm (before and after surgery or stent-graft place-
ment) in all cases of chronic dissection. Choice of imaging
modality may vary with institutional availability and
expertise, and also with the extent of aortic involvement
and age of the patient. Previous recommendations suggest
follow-up imaging and examination at 1, 3, 6, 9 and 12
months after discharge and annually thereafter.1,2 This
aggressive strategy supports the notion that both hyper-
tension and aortic expansion/dissection are common and
not easily predicted in the first months after hospital
discharge. Furthermore, imaging is not confined simply to
the region of initial involvement because both dissection
and aneurysm formation may occur anywhere along the
entire length of the aorta. The patients who have been
treated by open surgery and/or endovascular stent grafting
warrant similar a follow-up than those whose initial
strategy was limited to medical treatment alone.
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